Thiotepa Injection, Powder, Lyophilized, For Solution
Product Images NDC 25021-246

2 FDA label images from Sagent Pharmaceuticals · Packaging, Regulatory Labels, and Product Appearance

Product Visual Gallery

This gallery contains 2 technical images submitted to the FDA as part of the official labeling for Thiotepa (NDC 25021-246). Unlike standard consumer photos, these assets often include clinical data figures, molecular chemical structures, and official manufacturer packaging layouts.

As provided by Sagent Pharmaceuticals, these visuals offer a comprehensive scientific overview of the product's physical and chemical identity, aiding pharmacists and researchers in product verification and study.

Product Images & Figures Index

FDA Label Image

Thi02 0002 01

Thi02 0002 01
Chemical structure of Thiotepa, showing a phosphorus atom bonded to three aziridine rings and a sulfur atom, representing the lyophilized injection drug Thiotepa by Sagent Pharmaceuticals.*
FDA Label Image

Thi02 0002 02

Thi02 0002 02
Label for Thiotepa For Injection, USP at 15 mg per vial strength. It is a lyophilized powder for intravenous, intracavitary, or intravesical use. Label includes NDC 25021-246-02, cautioning that it is a cytotoxic agent. Manufactured for Sagent Pharmaceuticals with storage instructions and barcode present.*

* About these descriptions: Image descriptions on this page are generated by automated AI analysis of the product label images from the manufacturer's FDA label submission (SPL). They are provided for reference only and may contain errors or omissions. Always rely on the printed label itself and the official FDA labeling, and consult a pharmacist or healthcare professional with any questions about this product.